Neither of the trials were long enough to for us to report survival at one year. Combined results from the two studies (based on 274 participants) provided high-quality evidence of little or no difference in estimated one-year survival, the rate of decline in respiratory function, or rate of decline in arm strength in people treated with gabapentin compared to those treated with placebo. One trial (128 participants) measured quality of life and monthly decline in function (measured by the ALS Functional Rating Scale). There was little or no difference in the ALS Functional Rating Scale (ALSFRS) or quality of life between the gabapentin group and the placebo group.
People who received gabapentin had more light-headedness, drowsiness, and limb swelling than those taking placebo when we combined data from both trials (353 participants). Fatigue and falls occurred more frequently with gabapentin than with placebo in one trial, but when we combined the data for fatigue from both trials, there was no clear difference between the groups.
In conclusion, high-quality evidence indicates that gabapentin does not extend survival or slow the rate of decline of muscle strength or respiratory function. Moderate-quality evidence shows no effect on quality of life or decline in ALSFRS. Other GABA modulators have not been studied in randomized trials.
The evidence is current to August 2016.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Gabapentin compared with placebo for amyotrophic lateral sclerosis ( No clinically or statistically signif icant dif f erence between gabapentin and placebo Neither included study was long enough to report survival at one year, which was the prespecif ied prim ary outcom e of the review. Estim ated survival (gabapentin vs placebo) was 78% versus 77%, P = 0.63 by log-rank test)
Rate of decline in M VIC
Expressed as arm m egascore 1 M ean rate of arm m egascore decline in control groups was -0. 026 1 The m ean rate of arm m egascore decline in gabapentin groups (see com m ents) was:
• 0.005 less decline (0.002 more to -
(2 RCTs) ⊕⊕⊕⊕ High
We present the 2 trials separately with an adjustm ent f or dif f erences in slope between the two trials and 0.013 less)
• 0.004 more decline (0.010 more to 0.003 less) f or sym ptom duration. M iller 1996 had an unusually f ast rate of arm m egascore decline in the placebo group and a shorter treatm ent duration in the gabapentin group than the placebo group; both f actors had a signif icant ef f ect on arm m egascore decline No clinically or statistically signif icant diff erence in arm m egascore decline between treated and placebo groups in either trial
Rate of decline of % predicted FVC
The rate of FCV decline in control groups was0. 593 to 0.65 3 The m ean rate of FVC decline in the gabapentin group was 0.057 more decline (0. 21 more to 0.09 less) -
(2 RCTs) ⊕⊕⊕⊕ High
No clinically or statistically signif icant dif f erence between gabapentin and placebo Rate of decline (per month) of functional rating scale (over a period of 9 m onths) M easured by ALSFRS-R The control rate of decline of ALSFRS-R was 0.076 4 The rate of ALSFRS-R decline was 0.015 less decline (0.34 more to 0.05 less)
No clinically or statistically signif icant dif f erence between gabapentin and placebo
Health-related quality of life Short Form 12 Health Survey (SF-12)
M iller 2001 reported little or no dif f erence between treatm ent and placebo groups in the SF-12 (Physical), with a m ean change (± SD) of -0.03 (± 0.7) on gabapentin and -0.2 (± 0.5) on placebo (P = 0.19)
Adverse events
The trials did not report an overall adverse event rate. Light-headedness, drowsiness, f alls and swelling were reported in both trials and were signif icantly m ore com m on with gabapentin than with placebo. 1. This is the pooled m ean rate of decline f rom the two studies, as reported in M iller 2001. 2. We used a linear m ixed ef f ect m odel to account f or dif f erences in slopes between the two trials and f or sym ptom duration. One of the trials (the phase II, M iller 1996) had an unusually rapid placebo group decline. 3. The basis f or the assum ed risk is the com bined f it of FVC slopes f rom the 2 included studies. 4. The basis f or the assum ed risk is the placebo group ALSFRS-R slope. 5. We downgraded the evidence once f or im precision (sm all study size), as one study with 128 participants provided data f or this outcom e.
B A C K G R O U N D Description of the condition
Amyotrophic lateral sclerosis (ALS), which is also known as motor neuron disease (MND), Lou Gehrig's or Charcot's disease, is a neurodegenerative disorder characterized by loss of motor neurons of the cerebral cortex, brain stem, and spinal cord. The condition results in progressive weakness and paralysis of voluntary muscles, which ultimately leads to death. Median prevalence (per 100,000 population) has been estimated as 5. 
Description of the intervention
Pharmacological reversal of cortical hyperexcitability in people with ALS has been observed after sustained treatment with GABA modulators such as gabapentin (Caramia 2000) , even though experiments with rat neocortical slices found no effect of gabapentin on GABA release because of the selective activation of presynaptic GABA-B heteroreceptors (Parker 2004) . Baclofen is a GABA agonist with some efficacy in reducing spasticity of cerebral or spinal origin in people with ALS (Norris 1979).
How the intervention might work
The above studies indicate that the mechanism of action of gabapentin is still controversial (Taylor 1994; Taylor 1998) . They provided a rationale for undertaking clinical trials of gabapentin in ALS, despite the fact that gabapentin is not a structural analog of GABA (Satzinger 1994), but simply a compound with conformational properties that mimic its amino acid structure (Bryans 1999) . Although the evidence supporting a role for GABA is under debate, sufficient data exist to justify trials of the GABA agonist baclofen or the GABA modulator gabapentin in ALS.
Why it is important to do this review
While treatment for spasticity and cramps in ALS have been the subjects of other reviews (Ashworth 2012; Baldinger 2012), no systematic review has addressed the benefit of GABA modulators such as gabapentin or baclofen in slowing the clinical progression of ALS. Thus, the specific aim of this review is to assess the clinical impact of GABA modulators as disease-modifying agents.
O B J E C T I V E S
To examine the efficacy of gabapentin, baclofen, or other GABA modulators in delaying the progression of ALS, and to evaluate adverse effects of these interventions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered for inclusion double-blind, randomized controlled trials (RCTs) and quasi-RCTs of gabapentin, baclofen, or other GABA modulators in the treatment of ALS. Quasi-RCTs use methods of allocation that are partly systematic, such as allocation by alternate days, date of birth, or hospital number.
Types of participants
We considered for inclusion adults with a clinical and laboratorysupported diagnosis of probable or definite ALS that conformed to the criteria of the World Federation of Neurology (WFN) Research Group (Brooks 2000).
Types of interventions
We considered for inclusion gabapentin, baclofen, or other GABA modulators compared with placebo, no treatment, or each other.
Types of outcome measures Primary outcomes
Survival at one year from study enrollment.
Secondary outcomes
1. Individual rate of decline of maximum voluntary isometric contraction (MVIC), expressed as arm megascore.
2. Rate of decline of percent predicted forced vital capacity (FVC).
3. Rate of decline of ALS Functional Rating Scale (ALSFRS) (Cedarbaum 1999).
4. Health-related quality of life assessed by means of a validated multipurpose scale, such as the 36-Item Short Form Health Survey (Rand 2016).
5. Survival evaluated by pooling hazards using methods described by Parmar 1998 when study data are sufficiently detailed (i.e. when survival in each group is reported as numbers at risk and numbers dying at follow-up intervals, e.g. quarterly or semi-annually). If such data are not available for all studies, we will use other approaches, such as generalized inverse variance on reported hazard ratios and their standard errors.
6. Adverse events, namely side effects such as lightheadedness, drowsiness, weakness, daytime fatigue, nausea, anorexia, or weight loss. We based comparisons on analyses of 2 x 2 tables summarizing numbers of events in each group, regardless of time of occurrence. We planned to base measurement of rates on the length of followup for the trial. If the lengths of follow-up differed, we planned to conduct a subgroup analysis to determine whether length of follow-up influenced the rate of decline in different trials.
Search methods for identification of studies Electronic searches
On 16 
Searching other resources
We checked the bibliographies of the trials found in order to identify references to other trials. In addition, we contacted authors of trials to identify relevant unpublished results or clinical trials.
Data collection and analysis

Selection of studies
Two or three review authors (from among AD, DHM and RP) independently checked all titles and abstracts identified by the searches. The same review authors independently examined the full-text reports of the collected papers in order to select trials that fit the inclusion criteria for the review. There was no disagreement on study selection. We included a PRISMA flow chart to illustrate the study selection process and noted the reasons for study exclusion in sufficient detail for completion of a Characteristics of excluded studies table.
Data extraction and management
We were able to obtain the original data for each participant in all included trials from the trial authors, two of whom are authors of this review. For each study, we had original raw data for every participant for all outcome endpoints. We then combined all original data into one dataset, which facilitated statistical analyses. A statistician independent of the trials (AO'K) and the Managing Editor of Cochrane Neuromuscular double-checked the data in the review to ensure accuracy.
Assessment of risk of bias in included studies
Two review authors (AD and RP) independently assessed the risk of bias in each included study. We would have resolved disagreement by consensus, but none occurred. Each review author assessed the risk of bias of the studies, taking into account the following parameters: security of randomization, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, completeness of outcome data, selective outcome reporting, and other sources of bias, according to the methods set out in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We made judgements for each domain of low, high, or unclear risk of bias. We included a 'Risk of bias' summary figure showing the assessments for the included studies ( Figure 1 ). 
Data synthesis
We obtained Individual participant data for statistical analyses. We combined data from the two trials for meta-analysis where both trials reported the same outcome.
Statistical methods
We obtained data from the principal investigators for each participant in each of the clinical trials included in this review. For survival, we combined the data from the studies into a single data file and used the Kaplan-Meier method to estimate survival at 12 months after enrollment into the trial. We also used the log-rank statistic to test whether participants treated with gabapentin had longer survival than those treated with placebo. Both studies used rate of decline in arm megascore strength (MVIC) of eight arm muscle groups (bilateral shoulder and elbow flexion and extension) as their primary measure of efficacy. Both studies measured MVIC every four weeks. Raw scores for MVIC were standardized to published norms using z-score transformations (raw score minus norm average divided by norm standard deviation). The arm megascore was calculated as the average zscore over all tested muscles for each participant at each visit. The primary outcome measure was the mean slope of the arm megascores (rate of decrease over time, measured in days from initial visit), for each participant in the intent-to-treat population, which included all participants randomized to a study medication (active or placebo) and having at least two visits to the center. In the original analyses of each study a slope was estimated by linear regression for each participant and mean slopes for treated and placebo were compared using t-test or Mann-Whitney test. These analyses weighted each participant equally, regardless of the number of times each participant was evaluated.
In this meta-analysis, we pooled individual participant data from the trials and fit a linear mixed effects (lme) model to the combined data. This model takes into account the number of times each participant is evaluated so that those with more evaluations receive greater weight when estimating model parameters. The lme model also estimates pooled variances rather than separate ones when each participant is fit separately using linear regression. (The lme model was not available for the phase II study in 1996.) We also use the lme model to fit combined FVC data. Our statistical model assumed that arm megascore (transformed to average z-score) and FVC declined linearly over time. When fitting the pooled data, the lme model included fixed-effect terms for intercept (starting value), slope (rate of decline over time), and change in slope for gabapentin treatment. Random effects for intercept and slope allowed for person-to-person differences in slope and intercept and an additional random effect for each participant's deviation from the linear fit. The model is given mathematically by the formula: Yij = (B0 + b0i) + (B1 + B2*Ii + b1i)*Tij + eij, where i indicates participant and Tij indicates time (month of the jth measurement in the ith participant). Capital letters indicate fixed-effect coefficients and lower case letters are random effects. The term Ii is an indicator equal to 1 for the ith participant on active treatment and 0 for placebo. We also added fixed-effect terms to test whether treatment effects differed by trial, symptom duration, and initial arm megascore. We used Stata version 11.0 for the above statistical analyses (Stata 2009).
Other analyses
We calculated a risk ratio (RR) with 95% CI for adverse event outcomes using the Cochrane statistical software Review Manager 5 (RevMan) (RevMan 2014). We used a fixed-effect model for these analyses as the two included trials were performed with similar methods by the same investigators, and we consider them very likely to be measuring the same effects. We assessed heterogeneity in the meta-analyses visually and using the Chi² test and I² statistic calculated by RevMan. We followed guidance for rule of thumb interpretation of I² in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
'Summary of findings' table
We created a 'Summary of findings' table showing the following outcomes.
• Survival at one year from study enrollment.
• Rate of decline of MVIC.
• Rate of decline of per cent predicted FVC.
• Rate of decline (per month) of ALSFRS.
• Health-related quality of life.
• Adverse events.
We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence (studies that contribute data for the prespecified outcomes). We used methods and recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We used GRADEpro software (GRADE 2008) . We used footnotes to justify any decisions to downgrade or upgrade the quality of studies and made comments to aid readers' understanding of the review where necessary.
Sensitivity analysis
We would have performed sensitivity analysis to investigate heterogeneity in the results and to assess the effect of including studies at higher risk of bias, but this was not necessary.
R E S U L T S Description of studies
Results of the search
Several searches were run in each database over a number of years. The MEDLINE and Embase filters were changed to improve specificity during review development. See Figure 2 for a PRISMA flow chart illustrating the study selection process. The combined searches found the following total number of papers in each database.
• MEDLINE -40 papers • Embase -246 papers • Cochrane Neuromuscular Specialised Register -11 papers • CENTRAL -10 references • CINAHL Plus -7 references • AMED -0 references • LILACS -0 references
We considered six studies as potentially eligible after screening titles and abstracts, but only two RCTs fulfilled selection criteria for the review (Miller 1996; Miller 2001) .
Included studies
We identified two studies that fulfilled our selection criteria (Miller 1996; Miller 2001 ); see Characteristics of included studies. Both were randomized, placebo-controlled, double-blind studies based on the enrollment of people with a diagnosis of definite or probable ALS. In Miller 1996, the intervention consisted of oral gabapentin 800 mg or placebo three times daily for six months. During Miller 2001, participants received oral gabapentin 1200 mg three times daily or placebo for nine months.
Excluded studies
We excluded two studies that were not randomized (Caramia 2000; Kalra 2003). We excluded a nonblinded study on the grounds that randomized participants received different doses and schedules of gabapentin, and a nonrandomized group formed the control group (Mazzini 1998). In Norris 1979, very few baclofentreated participants completed the trial and all had a fatal outcome. The data were too meagre for analysis. See Characteristics of excluded studies.
Risk of bias in included studies
Both studies presented a low risk of bias overall. The Miller 1996 report did not describe allocation concealment; therefore, we rated this domain and blinding of participants as unclear. Miller 2001 was at low risk of bias for all domains other than selective outcome reporting. which we rated as at unclear risk of bias, because the trialists did not fully report adverse events. See the 'Risk of bias' summary figure for an illustration of the review authors' 'Risk of bias' assessments for each trial ( Figure 1) and Characteristics of included studies.
Effects of interventions
See: Summary of findings for the main comparison
Gabapentin versus placebo
Survival at one year
Not reported
Arm megascores
Overall, there was little or no difference in arm megascore decline between the gabapentin-treated group and placebo group. The original report of results from the phase III trial noted that symptom duration was significantly shorter for participants assigned to gabapentin than for participants assigned to placebo. This report also noted a difference in arm megascore rate of decline in the placebo groups between the two trials. To account for these factors, we added terms to the lme model to account for differences in slopes between the two trials and for symptom duration. Both of these factors were significant, that is, arm megascore slopes differed significantly in the two trials and symptom duration had a significant effect on slopes. Table 1 summarizes the results of fitting the combined arm megascore with the lme model (N = 345). Interestingly, when we fit data from each trial separately, the effect of gabapentin was positive (i.e. reduced slope) in the phase II trial and was negative (i.e. increased slope) in the phase III trial. However, neither effect was statistically significant, nor was there a statistically significant difference in effect (P = 0.19 for a differential effect; high-quality evidence). 
Forced vital capacity
Gabapentin had little or no effect on FVC slope in either trial (see Table 2 ). Analysis of the combined data (N = 344) also found no little or no effect of gabapentin on slope. The lme model did not have to be adjusted for differences in results in the two trials and symptom duration had no effect on FVC (high-quality evidence). 
Survival (pooled estimate)
There was little or no difference in estimated one-year survival between the gabapentin-treated group and the placebo group. Survival appeared to be better in the phase III study (Miller 2001) compared to the phase II study (Miller 1996) , but the log-rank test comparing survival by trial in all participants suggested that it could be due to chance (P = 0.11). Nevertheless, to avoid bias due to possible improvement in ALS survival over calendar time, we used a stratified log-rank statistic to test for a treatment effect in the combined data. This also showed little or no difference between the two groups (high-quality evidence). (We summarize results in Table 4 ). 
D I S C U S S I O N
Summary of main results
We identified two RCTs of gabapentin in ALS involving a total of 355 participants and performed a meta-analysis of the combined data. The trials were to short to provide data on survival a year after enrollment, which was the primary outcome of the review. However, there was little or no difference in estimated survival at one year in the gabapentin-treated group versus the placebo group in either trial, or in the combined data. The arm megascore was the primary outcome measure of both trials. Results from the phase II trial showed a trend toward a slowing of the decline of arm megascore, even though this difference did not reach a statistical significance (defined as P < 0.05) (Miller 1996) . Results from the randomized phase III trial (Miller 2001) , as well as analysis of the combined arm megascore data from both trials, showed no therapeutic benefit with gabapentin in people with ALS. FVC, the other major outcome measure in these studies, is still an important outcome measure in ALS trials because of the importance of pulmonary function to people with ALS. Here again, there was little or no benefit from treatment. One trial measured monthly decline in the ALSFRS and quality of life using the SF-12 and found that there was probably little or no difference between groups for ALSFRS and quality of life. Drowsiness, light-headedness, and limb swelling occurred more frequently with gabapentin than with placebo, based on combined analyses. Fatigue and falls occurred more frequently with gabapentin than with placebo in one trial, but when we combined the data for fatigue from both trials, there was no clear difference between the groups.
Overall completeness and applicability of evidence
In the absence of trials of baclofen and other GABA modulators, the identified trials of gabapentin fit the overall requirements for inclusion in the review. One of the trials did not measure quality of life or ALSFRS (Miller 1996) .
Quality of the evidence
We consider the two studies that were included to yield high-quality evidence that gabapentin is not effective in ALS. We did not consider these studies to be completely free of any risk of bias, but both had adequate blinding, sequence generation and outcome reporting. We therefore assessed the risk of bias in these trials as low.
We identified no reasons for downgrading the quality of the evidence based on the GRADE criteria of indirectness, inconsistency, publication bias, or study limitations. We downgraded quality of life and decline in ALSFRS outcomes for imprecision due to the small sample size (128 participants) of the one trial that provided data.
Potential biases in the review process
Review authors who were not investigators in the trials assessed risk of bias in the selected studies. DM was the statistician in both included studies and performed data extraction and entry for this review. He provided outcome data for checking by other review authors and the Cochrane Neuromuscular Managing Editor.
Agreements and disagreements with other studies or reviews
A Cochrane review reported that gabapentin had no benefit in trial participants with type II and III spinal muscular atrophy (SMA), which is another, more slowly progressive, motor neuron disease (Wadman 2012).
A U T H O R S ' C O N C L U S I O N S
Implications for practice
According to high-quality evidence, gabapentin is not effective in treating amyotrophic lateral sclerosis (ALS), because it neither halts nor slows progression of ALS. Gabapentin does not improve estimated survival at one year nor slow the rate of decline of muscle strength or respiratory function. Gabapentin probably has little or no effect on quality of life or monthly decline in ALS functional rating scale. No evidence from randomized trials was available for other gamma aminobutyric acid (GABA)-modulating treatments.
Implications for research
Further studies of gabapentin to slow progression of ALS are unlikely to be fruitful. The literature provides no indication of alternative promising GABA modulators.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Miller 1996
Methods Randomized, placebo-controlled, double-blind study 
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
RP replaced Valeria Sogos, who was an author of the Cochrane protocol (Diana 2006). AO'K joined the authors at the review stage.
The current Cochrane 'Risk of bias' methodology (Higgins 2011) replaced the assessment of methodological quality described in the protocol. We included a 'Summary of findings' table and PRISMA flow chart, according to Cochrane requirements developed since publication of the protocol.
This review has also reported adverse effects of included interventions; we analysed adverse events using risk ratios and 95% confidence intervals. We did not plan these analyses in the original protocol.
As a change from protocol, at least two and sometimes three authors independently checked titles and abstracts retrieved by the searches.
N O T E S
Further research in this area is unlikely and no update is currently planned for this review.
